Sedentary lifestyles, work overload, and lack of regular physical activity are risk factors for spinal pain syndrome. In everyday medical practice, spinal pain syndrome of a muscular or myofascial, or non-neurogenic, nature is diagnosed. This problem affects a large group of patients and reaches about 70–80% of spinal pain cases. Usually, one of the primary treatments is with NSAIDs (Non-steroidal Anti-Inflammatory Drugs). In this case, one treatment method that is safe and has no side effects is spinal mesotherapy. This method consists of performing multi-point intradermal microinjections with the administration of drugs or medical devices. Based on a new perspective on the treatment of spinal pathology—the so-called three-stage treatment concept—it is necessary to deal with the risk factor(s) of spinal pain syndrome and reduce or at least modify them (stage I). This is followed by a broadly understood medical therapy, in this case spinal mesotherapy (stage II), which aims to relax tense tissues, improve mobility in the spine and thus reduce pain. As a result, conditions are created for the necessary process, which is rehabilitation in the broadest sense (stage III). Movement therapy, which is crucial in spinal pain syndrome, is performed with less pain, after obtaining better patient mobility. The purpose of this article is to evaluate the role of rehabilitation of patients after spinal mesotherapy in terms of the three-stage treatment concept for spinal pathology.

Greater trochanter pain syndrome (GTPS) occurs in a large group of patients. This problem can affect patients of any age and is associated with a sedentary, overloading, and non-ergonomic lifestyle/work with a concomitant lack of regular physical activity. The literature to date describes the effectiveness of various therapies. Glucocorticosteroid injections and physical therapy are used. One of the new methods is injection collagen therapy using collagen type I (COL-I), a protein of porcine origin, which aims, among other things, to regenerate inflammation-changed tendon. Various repair mechanisms are activated, including the induction and proliferation of fibroblasts, as well as their migration to the pathological site. This is followed by stimulation and synthesis of COL-I, secretion, and maturation. Ultimately, a regenerative effect is achieved. This article aims to discuss the role of COL-I in the injectable treatment of GTPS as a new therapeutic approach.

Objectives: Thoracic spine pain syndrome is far less common than lumbosacral or cervical pain. This pathology is often caused by work-related overload, especially sedentary work, lack of regular sport activities, and adopting incorrect postures. Thoracic spine pain may result, for instance, from degenerative joint lesions. In consequence, there is a reflex contraction of the soft, paraspinal tissues (muscles, fascia, ligaments). In this case, one of the treatment methods is spinal mesotherapy. The purpose of the present research was to evaluate the effectiveness and safety of thoracic spinal mesotherapy with collagen type I vs. lignocaine.Material and methods: A retrospective analysis of the results of the treatment of patients with chronic thoracic back pain syndrome using mesotherapy was performed. A total of 130 patients (49 men and 81 women; mean age: 49 ±9 years) were divided into 2 groups: group A (n = 65), treated with collagen type I, and group B (n = 65), treated with lignocaine 1%. Mesotherapy was performed weekly over 5 weeks. Patients were assessed using the Visual Analogue Scale (VAS) and Laitinen scales before the therapy, after the therapy, and after a 3-month follow-up visit.Results: A statistically significant improvement was observed after the use of thoracic spinal mesotherapy both with collagen type I and lignocaine, on the VAS and Laitinen scales, with the collagen treatment having better results at the 3-month follow-up visit. No adverse effects were observed after the procedures.Conclusions: Spinal mesotherapy is an effective and safe method of treating chronic thoracic back pain syndrome using collagen type I and lignocaine. However, in an average observation, collagen mesotherapy seems to be more effective.

Back pain syndrome is one of the most prevalent disorders of the 21st century, frequently diagnosed by physicians across various medical specialties. A key clinical priority is to identify the underlying cause and establish an accurate diagnosis. A common etiological factor is the overload of soft tissues due to improper posture or movement, resulting in congestion, reduced mobility, and pain. Spinal mesotherapy, a minimally invasive injection technique, has gained attention for its ability to improve microcirculation, relax tense tissues, enhance range of motion, and, most importantly, alleviate pain. Increasingly, this treatment is being incorporated into a structured “three-step approach” to chronic back pain: risk factor assessment, medical intervention (such as spinal mesotherapy), and subsequent targeted physiotherapy. This narrative review analyzes nine studies involving more than 800 patients with chronic back pain syndrome. Across all included studies, mesotherapy demonstrated a consistent positive impact on both pain reduction and functional improvement, without reports of serious adverse events. The purpose of this review is to assess the current evidence on the efficacy and safety of spinal mesotherapy and to highlight its role within a multimodal treatment strategy for chronic back pain.

Background/Objectives: The number of patients with cervical spine pain has been increasing in recent years, and some have been diagnosed with chronic cervicocephalic syndrome (CCS). Collagen mesotherapy of the spine is increasingly being used to treat chronic pain syndromes. This retrospective observational study was conducted to evaluate the efficacy and safety of collagen mesotherapy in the course of CCS. Methods: The study included 31 patients (19 women and 12 men; mean age, 45.0 ± 10.1) with chronic CCS (>12 weeks) who underwent cervical spine mesotherapy using injectable collagen. Mesotherapy was performed at weekly intervals, in 5 (in 18 patients) and 6 (in 13 patients) sessions. Patients were assessed using the Visual Analogue Scale (VAS) for cervical spine pain, pain radiating to the occipital region, dizziness, and tinnitus before the start of mesotherapy, one week after its completion, and 3 months later during a follow-up visit. Changes over time were analyzed using the Friedman test for repeated measures and Cochran’s Q test for binary outcomes. Results: Following collagen mesotherapy, cervical pain on the VAS decreased from 7 (IQR 6–8) at baseline to 2 (IQR 1–3) after treatment and remained at 2 (IQR 1–2) after the 3-month follow-up (p < 0.001). The proportion of patients with occipital pain decreased from 100% to 38.7%, dizziness from 83.9% to 38.7%, and tinnitus from 19.4% to 6.5%. No adverse effects related to the therapy were observed. Conclusions: Collagen mesotherapy was associated with improvements in pain and accompanying symptoms in patients with chronic cervicocephalic syndrome, with no treatment-related adverse events observed. Nevertheless, further research in this area is necessary.